"1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid"@en . . . "For the treatment of adults (≥18 years of age) with the following infections caused by susceptible strains of the designated microorganisms: (1) uncomplicated urethral or cervical gonorrhea due to Neisseria gonorrhoeae, (2) uncomplicated urinary tract infections (cystitis) due to Escherichia coli, Staphylococcus epidermidis, or Staphylococcus saprophyticus, and (3) complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus epidermidis, or Enterobacter cloacae."@en . . . . "Rapidly absorbed following oral administration, with an absolute oral bioavailability of approximately 90%."@en . "\u00C9noxacine"@en . "74011-58-8"@en . "Enoxacin is approximately 40% bound to plasma proteins in healthy subjects and is approximately 14% bound to plasma proteins in patients with impaired renal function."@en . . . . "A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. [PubChem]"@en . . . "Plasma half-life is 3 to 6 hours."@en . "\"DrugSyn.org\":http://www.drugsyn.org/Enoxacin.htm"@en . "Enoxacinum"@en . . "Enoxacin"@en . "Enoxacino"@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "Enoxacin"@en . . "approved"@en . "Enteric bacteria and other eubacteria"@en . "Enoxacina"@en . . "Enoxacin exerts its bactericidal action via the inhibition of the essential bacterial enzyme DNA gyrase (DNA Topoisomerase II)."@en . "1-Ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid"@en . .